Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

61.20EUR
12:51pm BST
Change (% chg)

€0.16 (+0.26%)
Prev Close
€61.04
Open
€61.15
Day's High
€61.34
Day's Low
€60.27
Volume
1,446,154
Avg. Vol
3,464,380
52-wk High
€103.74
52-wk Low
€54.48

Latest Key Developments (Source: Significant Developments)

Bayer Says It Will Comply With California Court's Mediation Order
Friday, 12 Apr 2019 

April 12 (Reuters) - Bayer AG statement on decision in glyphosate litigation in California::* Will comply with court's mediation order in good faith.* Will remain focused on defending safety of glyphosate-based herbicides in court, including in Pilliod case, and through appeal in Johnson and post-trial proceedings in Hardeman.* Reliable science supports safety of Roundup.  Full Article

Novozymes Co And BioAg Announce Continuation With Bayer As Core Partner
Thursday, 4 Apr 2019 

April 4 (Reuters) - Novozymes ::CO AND BIOAG ANNOUNCE CONTINUATION WITH BAYER AS CORE PARTNER.CO IS PURSUING A MULTI-PARTNER SETUP, WITH TWO NEW PARTNERS, UNIVAR SOLUTIONS AND UPL.THE 2019 ORGANIC SALES GROWTH OUTLOOK FOR NOVOZYMES AND FOR THE AG & FEED BUSINESS IS MAINTAINED.THE LONG-TERM BIOAG TARGET OF SUPPLYING TECHNOLOGY TO 250-500 MILLION ACRES IS ALSO MAINTAINED.EBIT MARGIN,NET PROFIT GROWTH,FREE CASH FLOW BEFORE ACQUISITIONS AND ROIC GUIDANCE FOR 2019 UPDATED DUE TO ONE-OFF DEFERRED INCOME RELEASE.THE EBIT MARGIN GUIDANCE FOR 2019 IS INCREASED FROM 28-29% TO 29-30%.THE ROIC GUIDANCE FOR 2019 IS INCREASED FROM ABOUT 23% TO ABOUT 24%.NET PROFIT GROWTH GUIDANCE FOR 2019 INCREASED FROM 0-5% TO 5-10%.  Full Article

Bayer Statement In Reaction To Phase Two Verdict In Favor Of Plaintiff In Case Of Hardeman V Monsanto
Wednesday, 27 Mar 2019 

March 27 (Reuters) - Bayer AG ::BAYER STATEMENT IN REACTION TO PHASE TWO VERDICT IN FAVOR OF PLAINTIFF IN CASE OF HARDEMAN V MONSANTO.BAYER WILL APPEAL THIS VERDICT."DISAPPOINTED WITH JURY'S DECISION".VERDICT IN THIS TRIAL HAS NO IMPACT ON FUTURE CASES AND TRIALS, AS EACH ONE HAS ITS OWN FACTUAL AND LEGAL CIRCUMSTANCES .  Full Article

Bayer Says Phase III Clinical Trial With Nifurtimox Demonstrates Safety And Efficacy
Thursday, 14 Mar 2019 

March 14 (Reuters) - Bayer AG ::BAYER NEWS RELEASE: PHASE III CLINICAL TRIAL WITH BAYER’S NIFURTIMOX DEMONSTRATES SAFETY AND EFFICACY OF NEW FORMULATION TO TREAT CHILDREN WITH CHAGAS DISEASE.STUDY MET ITS PRIMARY ENDPOINT BY DEMONSTRATING SUPERIORITY OF 60-DAY NIFURTIMOX TREATMENT COMPARED WITH HISTORICAL PLACEBO CONTROL IN SEROLOGICAL RESPONSE AT ONE YEAR AFTER END OF TREATMENT.IN OVERALL STUDY POPULATION, SEROLOGICAL RESPONSE TO A SHORTER NIFURTIMOX TREATMENT DURATION OF 30 DAYS WAS LOWER WHEN COMPARED TO 60-DAY TREATMENT.  Full Article

Bayer - Application For Darolutamide Marketing in Japan
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Bayer AG ::BAYER SUBMITS DAROLUTAMIDE FOR MARKETING AUTHORIZATION IN JAPAN.REGULATORY SUBMISSION BASED ON POSITIVE DATA FROM PHASE III ARAMIS STUDY.SUBMITTED AN APPLICATION FOR MARKETING AUTHORIZATION IN JAPAN FOR DAROLUTAMIDE FOR THE TREATMENT OF PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC).  Full Article

Evotec Receives Payment For Chronic Cough Medicine Second Phase Trial
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Evotec AG ::DGAP-NEWS: EVOTEC RECEIVES MILESTONE PAYMENT FOR START OF SECOND PHASE II TRIAL IN ITS MULTI-TARGET ALLIANCE WITH BAYER.SMALL MOLECULE FROM ITS MULTI-TARGET ALLIANCE WITH BAYER HAS ADVANCED INTO PHASE II CLINICAL DEVELOPMENT FOR TREATMENT OF PERSISTENT CHRONIC COUGH.AS A RESULT OF TRIAL INITIATION, EVOTEC RECEIVED A PAYMENT OF EUR 3 M.  Full Article

Orion: Completion Of Rolling Submission Of NDA For Darolutamide To FDA
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - Orion Oyj ::ANNOUNCES COMPLETION OF ROLLING SUBMISSION OF NEW DRUG APPLICATION (NDA) FOR DAROLUTAMIDE TO THE U.S. FOOD AND DRUG ADMINISTRATION (FDA).CO'S PARTNER BAYER HAS BEEN GRANTED FAST TRACK DESIGNATION BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR DAROLUTAMIDE IN MEN WITH NMCRPC.  Full Article

Orion's And Bayer's Darolutamide Shows Substantial Efficacy And Favourable Safety Profile In Treatment Of Prostate Cancer In Aramis Trial
Thursday, 14 Feb 2019 

Feb 14 (Reuters) - Orion Oyj ::ORION'S AND BAYER'S DAROLUTAMIDE SHOWS SUBSTANTIAL EFFICACY AND A FAVOURABLE SAFETY PROFILE IN THE TREATMENT OF PROSTATE CANCER IN THE ARAMIS TRIAL.POSITIVE TREND IN OVERALL SURVIVAL WITH A 29% REDUCTION IN RISK OF DEATH AT INTERIM ANALYSIS OF DAROLUTAMIDE IN ARAMIS TRIAL.POSITIVE TREND IN OVERALL SURVIVAL WAS AOBSERVED, ALL OTHER SECONDARY ENDPOINTS DEMONSTRATED BENEFIT IN FAVOR OF DAROLUTAMIDE.  Full Article

Bayer Forms Research Alliance With Kyoto University
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - Bayer AG ::BAYER AND KYOTO UNIVERSITY FORM RESEARCH ALLIANCE TO DISCOVER NEW TREATMENT APPROACHES AGAINST LUNG DISEASES (REMOVES REDUNDANT WORDS).GOAL OF RESEARCH ALLIANCE IS TO IDENTIFY SPECIFIC TARGETS AND PATHWAYS THAT ARE CAUSING DISEASE AND TO DISCOVER NEW TREATMENTS TO MODULATE THESE PATHWAYS AND PREVENT FURTHER LUNG FUNCTION DECLINE.  Full Article

Petiq Inc Announces Amicable Legal Resolution
Tuesday, 22 Jan 2019 

Jan 22 (Reuters) - PetIQ Inc ::PETIQ, INC. ANNOUNCES AMICABLE LEGAL RESOLUTION.PETIQ INC - BAYER HEALTHCARE & CO'S SUPPLIER OF ADVECTA3 AND PETLOCK MAX HAVE RESOLVED BAYER'S PATENT INFRINGEMENT COMPLAINT REGARDING PRODUCTS.PETIQ INC - PETIQ TO CONTINUE OFFERING CUSTOMERS ITS ADVECTA3 AND PETLOCK MAX FORMULATIONS.  Full Article

Photo

Bayer shareholders vent ire over Monsanto-linked stock rout

BONN Bayer shareholders vented their anger over its stock price slump on Friday as litigation risks mount from the German drugmaker's $63 billion (£49 billion) takeover of seed maker Monsanto.